Question 1

What are bispecific antibodies in cancer treatment?

Accepted Answer

Bispecific antibodies are sophisticated molecular bridges that connect cancer cells directly to immune cells. Unlike traditional chemotherapy that attacks everything, these engineered proteins guide your body's natural defences precisely to cancer cells, creating more effective treatment with potentially fewer side effects.

Question 2

What is immuno-oncology and how does it work?

Accepted Answer

Immuno-oncology represents a fundamental shift in cancer treatment that trains your immune system to identify and destroy cancer cells naturally. Rather than directly attacking tumours with chemotherapy, it enhances the body's existing ability to recognise and eliminate threats, offering a more targeted approach.

Question 3

What is CAR T-cell therapy?

Accepted Answer

CAR T-cell therapy involves removing immune cells from patients, genetically modifying them to better fight cancer, and then reinfusing them back into the body. This cellular therapy approach has shown extraordinary results in certain blood cancers and represents personalised medicine at its most sophisticated level.

Question 4

How risky is investing in cancer therapy stocks?

Accepted Answer

Biotech investing in cancer therapies carries significant risk due to high drug development failure rates and substantial capital requirements. Even promising early results don't guarantee commercial success. However, successful treatments can capture enormous market share, offering potential for outsized returns alongside considerable risk.

Question 5

Best cancer therapy stocks to buy now?

Accepted Answer

The Cancer Therapies basket includes leading companies like Regeneron (bispecific antibodies), Moderna (mRNA cancer vaccines), and Gilead Sciences (CAR T-cell therapy). Rather than picking individual stocks, a diversified thematic approach helps spread risk across multiple innovative companies in this transformative sector.

Question 6

Should I invest in cancer therapy companies after Regeneron's breakthrough?

Accepted Answer

Regeneron's 100% response rate validates the entire bispecific antibody approach and provides proof of concept for technologies multiple companies are pursuing. This breakthrough often lifts prospects for the entire sector, though investors must weigh potential returns against biotech's inherent uncertainty.

Question 7

How to diversify cancer therapy investments?

Accepted Answer

Thematic investing through a Cancer Therapies basket provides exposure across multiple companies at different development stages with varying risk profiles. This approach reduces the impact of individual company setbacks whilst maintaining exposure to potential breakthroughs across the immuno-oncology sector.

Question 8

Why are cancer therapy stocks rising in 2024?

Accepted Answer

Regeneron's 100% complete response rate in lymphoma trials represents a watershed moment, demonstrating the transformative potential of immuno-oncology. Fast-track regulatory approval processes and rising global cancer incidence create favourable conditions for breakthrough therapies to reach market quickly.

Question 9

What companies are leading immuno-oncology innovation?

Accepted Answer

Regeneron focuses on bispecific antibodies, Moderna develops personalised mRNA cancer vaccines, and Gilead Sciences advances CAR T-cell therapy through Kite Pharma. These companies represent different innovative approaches within the broader immuno-oncology revolution transforming cancer treatment.

Question 10

When will new cancer treatments become widely available?

Accepted Answer

Health authorities worldwide have created fast-track approval processes for breakthrough cancer therapies, potentially accelerating time to market. Regeneron's success validates immuno-oncology approaches, though drug development timelines remain dependent on regulatory approval and commercial manufacturing capabilities.

Question 11

How to invest in cancer therapy stocks with small amounts?

Accepted Answer

Nemo's Cancer Therapies basket offers fractional shares starting from just £1, making thematic investing accessible to all budgets. The ADGM-regulated platform provides commission-free investing with AI-driven insights, allowing participation in breakthrough cancer treatment opportunities without requiring large capital.

Cancer Therapies: What's Next After 100% Response Rate

Cancer Therapies: What's Next After 100% Response Rate

Inside the $63bn Deal Reshaping AI Finance

Lula's Win Rattles Wall Street's Brazil Trio

DoorDash's $17bn Instacart Gambit Signals Delivery Wars Endgame

TikTok's Compute Hunger Could Redraw the Cloud Map

Bloom's Beat-and-Raise Hits a Cash Wall

Summary

That 100% Cancer Trial? A Cautious Investor's Guide

A Clever New Weapon

More Than a One-Trick Pony

A Sensible Punt in a Volatile World

Deep Dive

Market & Opportunity

Key Companies

Primary Risk Factors

Growth Catalysts

So investieren Sie in diese Chance

Häufig gestellte Fragen

Aktuelle Analysen

Inside the $63bn Deal Reshaping AI Finance

Lula's Win Rattles Wall Street's Brazil Trio

DoorDash's $17bn Instacart Gambit Signals Delivery Wars Endgame

TikTok's Compute Hunger Could Redraw the Cloud Map

Bloom's Beat-and-Raise Hits a Cash Wall

Inside the $63bn Deal Reshaping AI Finance

Lula's Win Rattles Wall Street's Brazil Trio

DoorDash's $17bn Instacart Gambit Signals Delivery Wars Endgame

TikTok's Compute Hunger Could Redraw the Cloud Map

Bloom's Beat-and-Raise Hits a Cash Wall